BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marchiani S, Tamburrino L, Nesi G, Paglierani M, Gelmini S, Orlando C, Maggi M, Forti G, Baldi E. Androgen-responsive and -unresponsive prostate cancer cell lines respond differently to stimuli inducing neuroendocrine differentiation. Int J Androl 2010;33:784-93. [PMID: 20088946 DOI: 10.1111/j.1365-2605.2009.01030.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Filon MJ, Gillette AA, Yang B, Khemees TA, Skala MC, Jarrard DF. Prostate cancer cells demonstrate unique metabolism and substrate adaptability acutely after androgen deprivation therapy. Prostate 2022. [PMID: 35980831 DOI: 10.1002/pros.24428] [Reference Citation Analysis]
2 Moraes de Farias K, Rosa-Ribeiro R, Souza EE, Kobarg J, Banwell MG, de Brito Vieira Neto J, Leyenne Alves Sales S, Roberto Ribeiro Costa P, Cavalcante Dos Santos R, Vilaça Gaspar F, Gomes Barreto Junior A, da Conceição Ferreira Oliveira M, Odorico de Moraes M, Libardi M Furtado C, Carvalho HF, Pessoa C. The Isoflavanoid (+)-PTC Regulates Cell-Cycle Progression and Mitotic Spindle Assembly in a Prostate Cancer Cell Line. Chem Biodivers 2022;19:e202200102. [PMID: 35362194 DOI: 10.1002/cbdv.202200102] [Reference Citation Analysis]
3 Dyshlovoy SA, Pelageev DN, Jakob LS, Borisova KL, Hauschild J, Busenbender T, Kaune M, Khmelevskaya EA, Graefen M, Bokemeyer C, Anufriev VP, von Amsberg G. Activity of New Synthetic (2-Chloroethylthio)-1,4-naphthoquinones in Prostate Cancer Cells. Pharmaceuticals (Basel) 2021;14:949. [PMID: 34681173 DOI: 10.3390/ph14100949] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Lin SR, Yeh HL, Liu YN. Interplay of Epidermal Growth Factor Receptor and Signal Transducer and Activator of Transcription 3 in Prostate Cancer: Beyond Androgen Receptor Transactivation. Cancers (Basel) 2021;13:3452. [PMID: 34298665 DOI: 10.3390/cancers13143452] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Su CY, Huang GC, Chang YC, Chen YJ, Fang HW. Analyzing the Expression of Biomarkers in Prostate Cancer Cell Lines. In Vivo 2021;35:1545-8. [PMID: 33910833 DOI: 10.21873/invivo.12408] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Li JM, Lee S, Zafar R, Shin E, Choi I. Sodium bicarbonate transporter NBCe1 regulates proliferation and viability of human prostate cancer cells LNCaP and PC3. Oncol Rep 2021;46:129. [PMID: 34013380 DOI: 10.3892/or.2021.8080] [Reference Citation Analysis]
7 Demirci S, Hayal TB, Kıratlı B, Şişli HB, Demirci S, Şahin F, Doğan A. Design and synthesis of phenylpiperazine derivatives as potent anticancer agents for prostate cancer. Chem Biol Drug Des 2019;94:1584-95. [PMID: 31148379 DOI: 10.1111/cbdd.13575] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Chen X, Shi H, Bi X, Li Y, Huang Z. Targeting the deubiquitinase STAMBPL1 triggers apoptosis in prostate cancer cells by promoting XIAP degradation. Cancer Lett 2019;456:49-58. [PMID: 31004702 DOI: 10.1016/j.canlet.2019.04.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
9 Miah S, Tharakan T, Gallagher KA, Shah TT, Winkler M, Jayasena CN, Ahmed HU, Minhas S. The effects of testosterone replacement therapy on the prostate: a clinical perspective. F1000Res 2019;8:F1000 Faculty Rev-217. [PMID: 30828436 DOI: 10.12688/f1000research.16497.1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Puca L, Vlachostergios PJ, Beltran H. Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies. Cold Spring Harb Perspect Med 2019;9:a030593. [PMID: 29844220 DOI: 10.1101/cshperspect.a030593] [Cited by in Crossref: 17] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
11 Namekawa T, Ikeda K, Horie-Inoue K, Inoue S. Application of Prostate Cancer Models for Preclinical Study: Advantages and Limitations of Cell Lines, Patient-Derived Xenografts, and Three-Dimensional Culture of Patient-Derived Cells. Cells 2019;8:E74. [PMID: 30669516 DOI: 10.3390/cells8010074] [Cited by in Crossref: 38] [Cited by in F6Publishing: 55] [Article Influence: 12.7] [Reference Citation Analysis]
12 Genc GE, Hipolito VEB, Botelho RJ, Gumuslu S. Lysophosphatidic acid represses autophagy in prostate carcinoma cells. Biochem Cell Biol 2019;97:387-96. [PMID: 30403494 DOI: 10.1139/bcb-2018-0164] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
13 Manca S, Frisbie CP, LaGrange CA, Casey CA, Riethoven JM, Petrosyan A. The Role of Alcohol-Induced Golgi Fragmentation for Androgen Receptor Signaling in Prostate Cancer. Mol Cancer Res 2019;17:225-37. [PMID: 30224543 DOI: 10.1158/1541-7786.MCR-18-0577] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
14 Wu CL, Chen CL, Huang HS, Yu DS. A new niclosamide derivatives-B17 can inhibit urological cancers growth through apoptosis-related pathway. Cancer Med 2018;7:3945-54. [PMID: 29953738 DOI: 10.1002/cam4.1635] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
15 Maina PK, Shao P, Liu Q, Fazli L, Tyler S, Nasir M, Dong X, Qi HH. c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer. Oncotarget 2016;7:75585-602. [PMID: 27689328 DOI: 10.18632/oncotarget.12310] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 6.3] [Reference Citation Analysis]
16 Lin TP, Chang YT, Lee SY, Campbell M, Wang TC, Shen SH, Chung HJ, Chang YH, Chiu AW, Pan CC, Lin CH, Chu CY, Kung HJ, Cheng CY, Chang PC. REST reduction is essential for hypoxia-induced neuroendocrine differentiation of prostate cancer cells by activating autophagy signaling. Oncotarget 2016;7:26137-51. [PMID: 27034167 DOI: 10.18632/oncotarget.8433] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 7.3] [Reference Citation Analysis]
17 Gao Q, Zheng J. Ginsenoside Rh2 inhibits prostate cancer cell growth through suppression of microRNA-4295 that activates CDKN1A. Cell Prolif 2018;51:e12438. [PMID: 29457293 DOI: 10.1111/cpr.12438] [Cited by in Crossref: 26] [Cited by in F6Publishing: 34] [Article Influence: 6.5] [Reference Citation Analysis]
18 Cheong JE, Zaffagni M, Chung I, Xu Y, Wang Y, Jernigan FE, Zetter BR, Sun L. Synthesis and anticancer activity of novel water soluble benzimidazole carbamates. European Journal of Medicinal Chemistry 2018;144:372-85. [DOI: 10.1016/j.ejmech.2017.11.037] [Cited by in Crossref: 37] [Cited by in F6Publishing: 45] [Article Influence: 9.3] [Reference Citation Analysis]
19 Ruan D, He J, Li CF, Lee HJ, Liu J, Lin HK, Chan CH. Skp2 deficiency restricts the progression and stem cell features of castration-resistant prostate cancer by destabilizing Twist. Oncogene. 2017;36:4299-4310. [PMID: 28346424 DOI: 10.1038/onc.2017.64] [Cited by in Crossref: 35] [Cited by in F6Publishing: 42] [Article Influence: 7.0] [Reference Citation Analysis]
20 Chang YT, Lin TP, Campbell M, Pan CC, Lee SH, Lee HC, Yang MH, Kung HJ, Chang PC. REST is a crucial regulator for acquiring EMT-like and stemness phenotypes in hormone-refractory prostate cancer. Sci Rep 2017;7:42795. [PMID: 28256535 DOI: 10.1038/srep42795] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
21 Delgado-González E, Sánchez-Tusie AA, Morales G, Aceves C, Anguiano B. Triiodothyronine Attenuates Prostate Cancer Progression Mediated by β-Adrenergic Stimulation. Mol Med 2016;22:1-11. [PMID: 26928389 DOI: 10.2119/molmed.2015.00047] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
22 Moritz T, Venz S, Junker H, Kreuz S, Walther R, Zimmermann U. Isoform 1 of TPD52 (PC-1) promotes neuroendocrine transdifferentiation in prostate cancer cells. Tumour Biol 2016;37:10435-46. [PMID: 26846108 DOI: 10.1007/s13277-016-4925-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
23 Dyshlovoy SA, Menchinskaya ES, Venz S, Rast S, Amann K, Hauschild J, Otte K, Kalinin VI, Silchenko AS, Avilov SA, Alsdorf W, Madanchi R, Bokemeyer C, Schumacher U, Walther R, Aminin DL, Fedorov SN, Shubina LK, Stonik VA, Balabanov S, Honecker F, von Amsberg G. The marine triterpene glycoside frondoside A exhibits activity in vitro and in vivo in prostate cancer. Int J Cancer 2016;138:2450-65. [PMID: 26695519 DOI: 10.1002/ijc.29977] [Cited by in Crossref: 41] [Cited by in F6Publishing: 50] [Article Influence: 6.8] [Reference Citation Analysis]
24 Weaver EM, Zamora FJ, Hearne JL, Martin-caraballo M. Posttranscriptional regulation of T-type Ca 2+ channel expression by interleukin-6 in prostate cancer cells. Cytokine 2015;76:309-20. [DOI: 10.1016/j.cyto.2015.07.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
25 Savelli G, Muni A, Falchi R, Zaniboni A, Barbieri R, Valmadre G, Minari C, Casi C, Rossini P. Somatostatin receptors over-expression in castration resistant prostate cancer detected by PET/CT: preliminary report of in six patients. Ann Transl Med 2015;3:145. [PMID: 26207238 DOI: 10.3978/j.issn.2305-5839.2015.06.10] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
26 Han J, Sohn EJ, Kim B, Kim S, Won G, Yoon S, Lee J, Kim MJ, Lee H, Chung K, Kim SH. Upregulation of death receptor 5 and activation of caspase 8/3 play a critical role in ergosterol peroxide induced apoptosis in DU 145 prostate cancer cells. Cancer Cell Int 2014;14:117. [PMID: 25506265 DOI: 10.1186/s12935-014-0117-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
27 Courel M, El Yamani FZ, Alexandre D, El Fatemi H, Delestre C, Montero-Hadjadje M, Tazi F, Amarti A, Magoul R, Chartrel N, Anouar Y. Secretogranin II is overexpressed in advanced prostate cancer and promotes the neuroendocrine differentiation of prostate cancer cells. Eur J Cancer 2014;50:3039-49. [PMID: 25307750 DOI: 10.1016/j.ejca.2014.09.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
28 Li P, Wang J, Chu M, Zhang K, Yang R, Gao WQ. Zeb1 promotes androgen independence of prostate cancer via induction of stem cell-like properties. Exp Biol Med (Maywood) 2014;239:813-22. [PMID: 24912507 DOI: 10.1177/1535370214538727] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
29 Pernicová Z, Slabáková E, Fedr R, Šimečková Š, Jaroš J, Suchánková T, Bouchal J, Kharaishvili G, Král M, Kozubík A, Souček K. The role of high cell density in the promotion of neuroendocrine transdifferentiation of prostate cancer cells. Mol Cancer 2014;13:113. [PMID: 24884804 DOI: 10.1186/1476-4598-13-113] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
30 Arenas Reyes NJ, Manuel Moreno LA, Carrillo Rodríguez AP, Fonseca Buitrago CL, Pompilio Daza Almendrales F. Diferenciación neuroendocrina en cáncer de próstata. Revisión de la literatura. Urología Colombiana 2014;23:39-43. [DOI: 10.1016/s0120-789x(14)50007-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
31 Gacci M, Baldi E, Tamburrino L, Detti B, Livi L, De Nunzio C, Tubaro A, Gravas S, Carini M, Serni S. Quality of Life and Sexual Health in the Aging of PCa Survivors. Int J Endocrinol 2014;2014:470592. [PMID: 24744780 DOI: 10.1155/2014/470592] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
32 De Petrocellis L, Ligresti A, Schiano Moriello A, Iappelli M, Verde R, Stott CG, Cristino L, Orlando P, Di Marzo V. Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. Br J Pharmacol 2013;168:79-102. [PMID: 22594963 DOI: 10.1111/j.1476-5381.2012.02027.x] [Cited by in Crossref: 95] [Cited by in F6Publishing: 104] [Article Influence: 11.9] [Reference Citation Analysis]
33 Kubisch R, Meissner L, Krebs S, Blum H, Günther M, Roidl A, Wagner E. A Comprehensive Gene Expression Analysis of Resistance Formation upon Metronomic Cyclophosphamide Therapy. Transl Oncol 2013;6:1-9. [PMID: 23418611 DOI: 10.1593/tlo.12295] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
34 Sagnak L, Topaloglu H, Ozok U, Ersoy H. Prognostic significance of neuroendocrine differentiation in prostate adenocarcinoma. Clin Genitourin Cancer. 2011;9:73-80. [PMID: 22035833 DOI: 10.1016/j.clgc.2011.07.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
35 Tamburrino L, Salvianti F, Marchiani S, Pinzani P, Nesi G, Serni S, Forti G, Baldi E. Androgen receptor (AR) expression in prostate cancer and progression of the tumor: Lessons from cell lines, animal models and human specimens. Steroids 2012;77:996-1001. [PMID: 22289337 DOI: 10.1016/j.steroids.2012.01.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
36 Danza G, Di Serio C, Rosati F, Lonetto G, Sturli N, Kacer D, Pennella A, Ventimiglia G, Barucci R, Piscazzi A, Prudovsky I, Landriscina M, Marchionni N, Tarantini F. Notch signaling modulates hypoxia-induced neuroendocrine differentiation of human prostate cancer cells. Mol Cancer Res 2012;10:230-8. [PMID: 22172337 DOI: 10.1158/1541-7786.MCR-11-0296] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 4.4] [Reference Citation Analysis]
37 Tai S, Sun Y, Squires JM, Zhang H, Oh WK, Liang CZ, Huang J. PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate 2011;71:1668-79. [PMID: 21432867 DOI: 10.1002/pros.21383] [Cited by in Crossref: 228] [Cited by in F6Publishing: 258] [Article Influence: 20.7] [Reference Citation Analysis]
38 Corona G, Baldi E, Maggi M. Androgen regulation of prostate cancer: where are we now? J Endocrinol Invest 2011;34:232-43. [PMID: 21297383 DOI: 10.1007/BF03347072] [Cited by in Crossref: 73] [Cited by in F6Publishing: 56] [Article Influence: 6.6] [Reference Citation Analysis]